In Vivo

Ring Therapeutics Turns To Anelloviruses To Disrupt Gene Therapy Space

05 Apr 2023

Ring Therapeutics is turning to a previously unexplored family of viruses to improve the safety and efficacy of gene therapy. The preclinical science suggests using these anelloviruses as vectors can deliver payloads precisely and without causing a significant immune response. Human trials will need to demonstrate the technology can live up to its disruptive potential.

A High Degree Of Tropism and Immune Evasion Make Anelloviruses An Attractive Gene Therapy Vector • Source: Ring Therapeutics

Tuyen Ong, CEO of Ring Therapeutics, is used to facing challenges: he fled Vietnam in the 1980s along with his parents, enduring difficult physical and psychological conditions as a child. Then, as a refugee and visible minority in London, England, Ong became the target of racism.

“I think the wounds – I sometimes describe them as blessings – toughened me up and gave me grittiness,” Ong...